A 28-year-old woman presents to the gynecology clinic with a 5-day history of purulent urethral discharge and dysuria. She is sexually active with a new partner. Gram stain of urethral exudate shows Gram-negative intracellular diplococci within neutrophils. Culture on Thayer-Martin medium yields oxidase-positive colonies. Nucleic acid amplification test (NAAT) confirms the diagnosis. What is the most appropriate first-line treatment for this patient?

Explanation

## Diagnosis & Treatment: Neisseria gonorrhoeae Urethritis **Key Point:** Acute urethritis with Gram-negative intracellular diplococci and oxidase-positive colonies on Thayer-Martin medium confirms *Neisseria gonorrhoeae* infection. Current CDC/WHO guidelines recommend ceftriaxone + azithromycin (or doxycycline) due to widespread resistance to penicillins and fluoroquinolones. ### Clinical Features of Gonococcal Urethritis | Feature | N. gonorrhoeae | N. meningitidis | C. trachomatis | |---------|----------------|-----------------|----------------| | **Site of infection** | Urethra, cervix, rectum, pharynx | Nasopharynx, meninges | Urethra, cervix, rectum | | **Discharge** | Purulent, copious | Absent | Mucopurulent, scanty | | **Gram stain** | Gram-neg intracellular diplococci | Gram-neg extracellular diplococci | Not visible on Gram stain | | **Culture medium** | Thayer-Martin (selective) | Blood agar, chocolate agar | Cannot culture on routine media | | **Fermentation** | Glucose only | Glucose + maltose | No fermentation | | **Incubation time** | 24–48 hours | 24–48 hours | Requires cell culture/NAAT | **High-Yield:** Gonococcal urethritis presents with acute onset of purulent discharge and dysuria 2–5 days after exposure. Meningococcal infection does NOT cause urethritis or genital discharge. ### Current Treatment Guidelines (2023 CDC/WHO) 1. **First-line: Ceftriaxone 250 mg IM (single dose) + Azithromycin 1 g PO (single dose)** - Ceftriaxone: covers both susceptible and moderately resistant strains - Azithromycin: covers potential co-infection with *Chlamydia trachomatis* (present in 20–40% of gonococcal cases) - **Rationale:** Emerging cephalosporin resistance necessitates combination therapy 2. **Alternative (if azithromycin unavailable): Ceftriaxone 250 mg IM + Doxycycline 100 mg PO twice daily for 7 days** ### Why Other Options Are Incorrect ```mermaid flowchart TD A[N. gonorrhoeae infection]:::outcome --> B{Treatment choice?}:::decision B -->|Penicillin G| C[Resistance common since 1980s]:::urgent B -->|Tetracycline| D[Suboptimal efficacy, resistance]:::urgent B -->|Fluoroquinolone| E[Widespread resistance, no longer recommended]:::urgent B -->|Ceftriaxone + Azithromycin| F[First-line, covers resistance & co-infection]:::action C --> G[Treatment failure]:::outcome D --> G E --> G F --> H[Cure & prevention of complications]:::outcome ``` **Mnemonic:** **GONORRHEA TREATMENT** = **G**o with **C**ephalosporin (**C**eftriaxone) + **A**zithromycin = **CA** (Current & Adequate) ### Resistance Patterns Over Time | Antibiotic | 1970s | 1990s | 2010s | 2023 Status | |------------|-------|-------|-------|-------------| | **Penicillin** | Susceptible | Resistant (PPNG) | Resistant | Obsolete | | **Tetracycline** | Susceptible | Resistant (TRNG) | Resistant | Obsolete | | **Fluoroquinolone** | Susceptible | Susceptible | Resistant (QRNG) | Not recommended | | **Cephalosporin** | Susceptible | Susceptible | Susceptible (emerging resistance) | First-line | **Clinical Pearl:** Penicillin-resistant *N. gonorrhoeae* (PPNG) emerged in the 1970s–80s and became widespread by the 1990s. Fluoroquinolone-resistant *N. gonorrhoeae* (QRNG) emerged in the 2000s and is now prevalent globally. Cephalosporin resistance is emerging but remains rare; combination therapy with azithromycin or doxycycline is now standard to prevent resistance and cover co-infections. **Warning:** Do NOT use penicillin, tetracycline, or fluoroquinolones as monotherapy for gonorrhea — resistance is widespread and treatment failure is common.